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Summary Indocyanine green (ICG) is clinically approved for the determination of liver function, cardiac output and plasma volume. In this
pilot study, ICG was used as photosensitizer in combination with a diode laser to treat AIDS-associated Kaposi's sarcoma (KS) in three
patients. Directly and up to 50 min after intravenous administration of ICG (2-4 mg kg-' body weight), KS (n = 57), mainly plaque-type, were
irradiated using a diode laser (item = 805 nm, 100 J cm-2, 0.5-5W cm-2) matching the absorption maximum. Complete remission of KS
(n = 16) was achieved when irradiated 1-30 min after injection of the second dose of ICG (2 x 2 mg kg-' b.w., 30 min apart) with 3-5 W cm-2
and 100 J cm-2. Biopsies (n = 3) revealed necrosis of the tumour 24 h and complete remission 4 weeks after therapy. In general, systemic
side-effects were not observed and cosmetic results were very good. However, hyperpigmentation occurred temporarily in lesions located on
the lower extremities. These findings show that AIDS-associated KS can be effectively treated after photosensitization with ICG and
subsequent irradiation with an appropriate diode laser. However, additional investigations need to elucidate the exact mechanism of action of
ICG-mediated phototherapy and have to show the efficacy for the treatment of other highly vascularized solid tumours.
Keywords: Kaposi's sarcoma; indocyanine green; tumour; laser; phototherapy
The most common malignancy observed in patients infected with
HIV is Kaposi's sarcoma (KS) (Lilenbaum and Ratner, 1994),
which is found as primary AIDS-defining illness in 15% of all
cases (Beral et al, 1990). The causal role of a KS-associated
herpesvirus in the pathogenesis of KS is discussed (Whitby et al,
1990). KS is a solid tumour consisting of cells of endothelial and
fibroblast origin. An insufficient angiogenesis is a prominent
feature of KS, resulting in extensive hypervascularization and
hyperperfusion ofthe tumour (Leu et al, 1994).
Although rarely life threatening, KS is often associated with
significant morbidity. Patients with KS suffer from cosmetically
disfiguring tumours that can appear all over the body and may
result in social stigmatization. Therapeutic approaches range from
observation, cryotherapy, intralesional injection of different thera-
peutic agents, to radiotherapy, systemic therapy with interferons,
antiretroviral agents and cytotoxic chemotherapy (Lilenbaum and
Ratner, 1994). However, treatment for AIDS-associated KS is
mostly palliative, and the optimal therapy exhibiting good thera-
peutic efficacy and tolerability, no side-effects and good cosmetic
results has not yet been found.
Indocyanine green (ICG) is a water-soluble tricarbocyanine dye
(MW 775) that was first approved for clinical use in humans in
1956 (Fox et al, 1956; Fox and Wood, 1960). After intravenous
injection ICG is bound to plasma proteins, in 80% to globulins,
mainly ax-lipoproteins (MW 200 000) (Muckle, 1976), and thus is
confined to the intravascular space. Under physiological condi-
tions ICG is exclusively eliminated from the blood through liver
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and excreted chemically unchanged into bile. There is no entero-
hepatic circulation. In human plasma, the maximal spectral
absorption is at a wavelength of 805 nm, farbeyond the absorption
maximum ofhaemoglobin and melanin. Owing to these character-
istics, ICG is clinically approved for determination of liver func-
tion (Paumgartner, 1975), plasma volume (Haller et al, 1993) and
cardiac output (Lund-Johansen, 1960).
Experimental solid tumours, for example amelanotic melanoma
of the hamster (A-MEL-3), show an increased microvascular
density and permeability resulting in higher fluorescence intensity
in tumour compared with surrounding tissue after i.v. injection of
ICG (unpublished data). Moreover, targeting of the fragile tumour
microvasculature by a photosensitizer and light irradiation (photo-
dynamic therapy) is a promising therapeutic modality for solid
tumours ('vascular targeting') (Denekamp, 1993).
Therefore, we supposedthatICG localized in the microvasculature
and extravascular space of solid tumours might be used as a photo-
sensitizer in combination with irradiation by a diode laser
(kXem = 805 nm) matching the absorption maximumofICG in plasma.
In the present study the effectiveness ofICG-mediated phototherapy
forthe treatment ofAIDS-associated Kaposi's sarcoma is shown.
METHODS
Three homosexual men aged 33, 34 and 67 years with AIDS-asso-
ciated, biopsy-proven KS were treated after having given informed
consent (Table 1). The patients presented with multiple (n =
10-50) macular, plaque-type and nodular KS lesions of minimum
0.4 cm and maximum 2.0 cm in diameter on the trunk and extrem-
ities (Figure 1A). None of the patients had visceral or mucocuta-
neous lesions. Besides KS, the patients did not reveal any other
apparent AIDS-related disorders.
ICG (ICG-Pulsion, Munich, Germany) was dissolved in an
aqueous solvent (50 mg of ICG in 10 ml of solvent) and injected
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Table 1 Patient data and treatment parameters
Demographic Number of Type of ICG Time between Light Response Follow-up
data lesions KS dose injection/ treatment
treated irradiation CR PR
33 years/male 51 Macular, (7) 2-4 0-50 min 0.5-5 W cm-2; n= 16 n=35 15 months
Nodular (3) mg kg-' 100 Jcm-2 (2 x 2 mg kg-1 (2 x 1 mg kg-'
Plaque (4) b.w. b.w., irradiation b.w., irradiation
type within 30 min, exceeding
3-5 W cm-2) 30 min, 0.5-
3W cm-2)
31 years/male 2 Plaque (2) 2 5 and 6 min 0.5W cm-2; - n = 2 6 months
type mg kg-' 100 Jcm-2 (2 x 1 mg kg-'
b.w. b.w.)
67 years/male 4 Nodular (2) 4 0-50 min 3 W cm-2; n = 2 n = 2 6 months
Plaque (2) mg kg-' 100 J cm-2 (plaque type; (nodular type;
type b.w. 2x2mgkg-' 2x2mgkg-1
b.w., irradiation b.w., irradiation
within 30 min) exceeding
30 min)
as bolus into the antecubital vein. Patients also received 7.5 mg of
piritramid i.v. (Dipidolor, Janssen-Cilag, Neuss, Germany) to
avoid pain during irradiation. ICG dosage and laser power varied
from 2.0 mg to 4.0 mg kg-1 b.w. (applied in two dosages within
30 min) and from 0.5 to 5 W cm-2 respectively. Irradiation by a
diode laser (Xem = 805 nm; beam diameter 2 cm; Opto Power,
Tucson, AZ, USA) was performed between 1 and 50 min after the
second injection of ICG with a total light dose of 100 J cm-2. A
total number of 57 mostly plaque-type KS lesions were treated in
several sessions (Table 1). For comparison, tumour tissue and
normal skin were irradiated before injection of ICG, as well as
normal skin after injection of ICG. Surface skin temperature was
measured by a thermocouple before and immediately after irradia-
tion. The clinical response was evaluated immediately, 24 h, 48 h,
1 week and 4 weeks after irradiation. Follow-up was continued for
up to 1 year after treatment. Complete response was defined as
absence of any detectable residual tumour; partial response was
defined as a 50% or greater decrease in the size of previously
existing lesions. Biopsies were taken 24 h (n = 2) after irradiation
and 4 weeks (n = 1) after therapy.
Fluorescence images were obtained using a fluorescence micro-
scope (Leitz, Munich, Germany; Xex = 750 nm, Xem . 770 nm;
Osram HBO 100 W) equipped with a SIT video camera
(C2400-08; Hamamatsu, Herrsching, Germany) and recorded on
videotape (VO-5850, Sony, Munich, Germany).
RESULTS
After injection of ICG (2 mg kg-1 b.w.) fluorescence intensity
increased in the observed KS lesion as well as in surrounding skin.
Twelve minutes after injection, KS lesions exhibited a higher fluo-
rescence intensity compared with surrounding skin (Figure 2A and
B), indicating a selective extravasation ofICG in the tumour.
Normal skin treated with ICG-mediated phototherapy or laser
alone showed erythema after irradiation, but neither necrosis nor
scar formation occurred. Tumour tissue treated with laser alone
(5 W cm-2) showed erythema after irradiation and superficial
tumour necrosis; however, lesions continued to progress after
treatment.
In KS, blanching of the tumour and erythema of surrounding
skin occurred immediately after irradiation of the previously
injected dye. One day after therapy, blistering and necrosis of
tumour area was observed (Figure iB). The mean temperature
increase in KS lesions immediately after irradiation was
12.1°C ± 4.4. Control lesions irradiated with 5 W cm-2 and
100 J cm-2 without ICG showed only a temperature increase of
4.7°C ± 1.1. Clinical examination (Figure IC) and histopatholog-
ical evaluation revealed complete remission of those KS (n = 16)
that had been irradiated approximately 10-30 min after the second
ICG injection (2 x 2 mg kg-1 b.w.) with a light intensity of 3-5 W
cm-2 and a total light dose of 100 J cm-2. The treatment depth was
c. 3.5 mm as measured in the histological sections. In contrast,
lesions showed only partial response when treated at a later time
after injection of lower doses of ICG (< 4 mg kg-' b.w.) with light
intensities < 3 W cm-2. No signs of recurrence of lesions with
complete remission were observed during the follow-up period
(Table 1). Cosmetic results were very good; scarring was hardly
visible. However, in lesions located on the lower extremities
hyperpigmentation occurred temporarily for several weeks.
DISCUSSION
This report shows that AIDS-associated KS, a hypervascularized
solid tumour, can be selectively sensitized and effectively treated
using i.v. administered ICG in conjunction with irradiation from a
diode laser matching the absorption maximum (kem = 805 nm)
(ICG-mediated phototherapy).
ICG-mediated phototherapy requires only the control of liver
function, whereas most therapies for AIDS-associated KS, for
example chemotherapy, interferon-cc, have to considerthepatient's
clinical status or rely on a 'functioning' immune system.
Moreover, a major advantage ofICG as photosensitizer is the clin-
ical approval of this safe and non-toxic (Speich et al, 1988) drug.
In addition, the near infrared absorption maximum of ICG allows
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A
Figure 1 Plaque-type AIDS-associated Kaposi's sarcoma on the back of a
33-year-old man, before (A), 24 h after lCG-mediated phototherapy
(irradiation with 5W cm-2, 100 J cm -2) (B) and after 3 months showing
(C) clinically complete remission
the use of a diode laiser (Xem = 805 nm) yielding deeper light pene-
tration into skin compared with argon-pumped dye lasers (kem =
630 nm), resulting probably in necrosis of the tumour down to the
dermis. Owing to the chemical properties of ICG, prolonged cuta-
neous photosensitivity was not observed in our patients after treat-
ment. Tolerability of the therapy was very good after injection of
an analgesic because of burning sensations. Excellent cosmetic
results were obtained after therapy of lesions located on the trunk,
whereas hyperpigmentation occurred temporarily when the lesions
A
B
Figure 2 Photograph (A) of macular Kaposi's sarcoma on the trunk of
patient 1 and corresponding fluorescence image (B) 12 min after injection of
ICG (2 mg kg-' b.w.; X* = 750 nm, X.m > 770 nm) showing higher
fluorescence intensity in the tumour compared with surrounding skin
were located on the lower extremities. Repeated treatments within
short intervals may be performed as ICG is eliminated from
the blood within 15 min and rapidly excreted by the liver.
Interestingly, a temperature rise of 12.1°C ± 4.4 was measured on
the KS-overlying skin directly after irradiation, indicating that
photothermal effects might be responsible for the therapeutic
effect.
A larger study is being initiated to determine the exact mecha-
nism of action, optimal treatment parameters and the efficacy in
the treatment of other solid tumours with increased microvascular
density and permeability.
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